Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Drakaki · SciRah

Researcher profile · Semantic Scholar

A. Drakaki

Share profile

A. Drakaki — researcher profile on SciRah

h-index: 40
Works: 315
Citations: 8,970

Most-cited papers

Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
T. Powles, B. Valderrama, Shilpa Gupta, J. Bedke +20 more
2024New England Journal of Medicine825 citations Open access
Semantic Scholar
Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trial.
T. Powles, van der Heijden, Y. Loriot, J. Bedke +17 more
2025Annals of Oncology78 citations Open access
Semantic Scholar
Atezolizumab monotherapy for metastatic urothelial carcinoma: final analysis from the phase II IMvigor210 trial
J. Rosenberg, M. Galsky, T. Powles, D. Petrylak +20 more
2024ESMO Open41 citations Open access
Semantic Scholar
NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025.
T. Gilligan, Daniel W. Lin, N. Adra, A. Bagrodia +31 more
2025The Journal of the National Comprehensive Cancer Network33 citations
Semantic Scholar
1967MO Preliminary efficacy and safety of disitamab vedotin (DV) with pembrolizumab (P) in treatment (Tx)-naive HER2-expressing, locally advanced or metastatic urothelial carcinoma (la/mUC): RC48G001 cohort C
M. Galsky, V. Koshkin, M. T. Campbell, A. Drakaki +13 more
2024Annals of Oncology31 citations Open access
Semantic Scholar
EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
T. Powles, M. S. van der Heijden, Y. Loriot, J. Bedke +16 more
2025Journal of Clinical Oncology22 citations
Semantic Scholar
PD-1 blockade plus cisplatin-based chemotherapy in patients with small cell/neuroendocrine bladder and prostate cancers
Yi-Qian Gu, Ann Ly, S. Rodríguez, Han-Wei Zhang +10 more
2024Cell Reports Medicine16 citations
Semantic Scholar
Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma
van der Heijden, T. Powles, S. Gupta, Y. Loriot +21 more
2025ESMO Open15 citations Open access
Semantic Scholar
ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study.
S. Srour, J. Chahoud, A. Drakaki, B. Curti +12 more
2025Journal of Clinical Oncology14 citations Open access
Semantic Scholar
Datopotamab deruxtecan (Dato-DXd) in locally advanced/metastatic urothelial cancer: Updated results from the phase 1 TROPIONPanTumor01 study.
F. Meric-Bernstam, O. Alhalabi, A. Lisberg, A. Drakaki +13 more
2025Journal of Clinical Oncology14 citations Open access
Semantic Scholar
SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma
T. Powles, E. Grande, Nimira Alimohamed, Niara Oliveira +10 more
2025Future Oncology12 citations Open access
Semantic Scholar
1970MO Circulating tumor DNA (ctDNA) clearance with neoadjuvant durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) for cisplatin-ineligible muscle-invasive bladder cancer (MIBC) from the safety run-in cohort of the phase III VOLGA trial
A. Drakaki, T. Powles, Y. Wang, M. Bupathi +7 more
2024Annals of Oncology12 citations Open access
Semantic Scholar
Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor.
D. Bakaloudi, Rafee Talukder, D. Makrakis, L. Diamantopoulos +33 more
2024Clinical Genitourinary Cancer11 citations
Semantic Scholar
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
A. Tsimberidou, Farah A. Alayli, Kwame Okrah, A. Drakaki +36 more
2024Journal of Experimental Medicine11 citations Open access
Semantic Scholar
Real-world multicenter study of PD-1 blockade in HIV-associated classical Hodgkin lymphoma across the United States
K. Lurain, T. El Zarif, R. Ramaswami, Amin H. Nassar +26 more
2024Clinical Lymphoma, Myeloma & Leukemia11 citations Open access
Semantic Scholar
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes.
D. Bakaloudi, Rafee Talukder, T. Enright, Jacob B. Leary +41 more
2025Clinical Genitourinary Cancer10 citations
Semantic Scholar
A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER-1.
G. Iyer, Hiromichi Ebi, Natalie Cook, Xin Gao +16 more
2025Journal of Clinical Oncology10 citations Open access
Semantic Scholar
Datopotamab deruxtecan in locally advanced/metastatic urothelial cancer: Preliminary results from the phase 1 TROPION-PanTumor01 study.
A. Lisberg, A. Drakaki, F. Meric-Bernstam, O. Alhalabi +11 more
2024Journal of Clinical Oncology10 citations
Semantic Scholar
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
M. Galsky, M. S. van der Heijden, James W. F. Catto, H. Al-Ahmadie +16 more
2025Journal of Clinical Oncology9 citations
Semantic Scholar
Casdatifan (Cas) monotherapy in patients (pts) with previously treated clear cell renal cell carcinoma (ccRCC): Safety, efficacy and subgroup analysis across multiple doses from ARC-20, a phase 1 open-label study.
T. Choueiri, Jae Lyun Lee, Jaime Merchan, A. Patnaik +15 more
2025Journal of Clinical Oncology8 citations
Semantic Scholar
Phase 3 open-label, randomized, controlled study of disitamab vedotin with pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
M. Galsky, E. Grande, A. Necchi, M. Koontz +7 more
2024Journal of Clinical Oncology8 citations
Semantic Scholar
Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Shilpa Gupta, J. Bedke, M. S. van der Heijden, B. Valderrama +16 more
2025Journal of Clinical Oncology7 citations Open access
Semantic Scholar
Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study
A. H. Nassar, Sarah Abou Alaiwi, T. El Zarif, R. Denu +58 more
2025Journal for ImmunoTherapy of Cancer7 citations Open access
Semantic Scholar
Combination casdatifan plus cabozantinib expansion cohort of phase 1 ARC-20 study in previously treated patients with clear cell renal cell carcinoma.
T. Choueiri, M. Ornstein, Pedro C. Barata, M. Matrana +15 more
2025Journal of Clinical Oncology6 citations Open access
Semantic Scholar
Linking Baseline PSMA PET–Derived Parameters to Toxicity, Adverse Events, Pain, and Quality of Life in Patients Treated with [177Lu]Lu-PSMA-617: A Single-Center Retrospective Study
V. Murthy, Koichiro Kimura, L. Theus, Andrew T Nguyen +15 more
2025Journal of Nuclear Medicine6 citations
Semantic Scholar
Risk of severe immune-related adverse events in cancer patients with pre-existing autoimmunity receiving immune checkpoint inhibitor therapy
Dayna J. Isaacs, N. Kathuria-Prakash, Robin Hilder, M. Lechner +1 more
2024Current Cancer Reports5 citations Open access
Semantic Scholar
MicroRNAs in Genitourinary Malignancies: An Exciting Frontier of Cancer Diagnostics and Therapeutics
N. Kathuria-Prakash, Pranali R Dave, Lizette Garcia, P. Brown +1 more
2024International Journal of Molecular Sciences5 citations Open access
Semantic Scholar
Activity and biomarker analyses with casdatifan (cas), a next-generation HIF-2α inhibitor, in refractory clear cell renal cell carcinoma (ccRCC): Results from ARC-20.
T. Choueiri, Jaime Merchan, A. Patnaik, A. Drakaki +16 more
2026Journal of Clinical Oncology3 citations
Semantic Scholar
Preliminary results from a first-in-human phase 1 dose escalation trial of ADRX-0706, a next generation Nectin-4 ADC, in subjects with advanced solid tumors.
A. Drakaki, J. Call, S. Chandana, Jordi Rodon Ahnert +10 more
2025Journal of Clinical Oncology3 citations Open access
Semantic Scholar
ADARp150 counteracts whole genome duplication
Frank van Gemert, A. Drakaki, I. Lozano, Daniël C. de Groot +7 more
2024Nucleic Acids Research3 citations Open access
Semantic Scholar
Cytokine specificity in macrophages: JAK-STAT and beyond.
Josje M. A. Huisman, A. Drakaki, Thomas Decker, Marten A. Hoeksema
2026Trends in immunology2 citations Open access
Semantic Scholar
RC48G001: A phase 2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
T. Powles, V. Koshkin, J. Rosenberg, Nobuaki Matsubara +16 more
2026Journal of Clinical Oncology2 citations Open access
Semantic Scholar
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma
M. Galsky, A. Drakaki, Arnab Basu, B. McGregor +14 more
2026Future Oncology2 citations Open access
Semantic Scholar
Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy
A. Holzgreve, Christine E. Mona, Koichiro Kimura, Xinmin Li +8 more
2025Journal of Nuclear Medicine2 citations Open access
Semantic Scholar
3073P Enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC): An exploratory analysis in older patients (pts) and those with comorbidities from EV-302
N. Mar, S. Gupta, T. Powles, J. Bedke +16 more
2025Annals of Oncology2 citations Open access
Semantic Scholar
Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001).
M. Galsky, E. Grande, A. Necchi, A. Drakaki +5 more
2024Journal of Clinical Oncology2 citations
Semantic Scholar
Abstract CT138: Evaluating nivolumab (nivo) plus ipilimumab (ipi) in patients with metastatic castration-resistant prostate cancer (mCRPC): Clinical and translational results from the AMADEUS prostate expansion cohort
A. Tsimberidou, A. Drakaki, D. Khalil, Kwame Okrah +16 more
2024Cancer Research2 citations
Semantic Scholar
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma.
Rafee Talukder, D. Bakaloudi, D. Makrakis, L. Diamantopoulos +30 more
2024Clinical Genitourinary Cancer2 citations
Semantic Scholar
Insurance remains a major source of disparity for patients with testicular cancer: call for advocacy
Savannah Starr, J. Zhang, Lin Lin, Jolie Z. Shen +4 more
2024BJU International2 citations Open access
Semantic Scholar
Artificial intelligence (AI) as a practical decision support tool for oncologists: Genitourinary (GU) cancer cases.
M. Jahanzeb, K. Haines, Erin L. Shonkwiler, M. Kiyani +2 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Real-World Toxicity and Efficacy Profile of Enfortumab Vedotin With or Without Pembrolizumab in Ultra-Elderly Patients With Advanced Urothelial Carcinoma.
N. Mar, Marsenne Y. Cabral, Jeanah Go, D. Kaakour +3 more
2026JCO Oncology Practice1 citations
Semantic Scholar
Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial
S. Srour, J. Chahoud, A. Drakaki, Brendan D. Curti +12 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
Revealing an unconventional JAK1/2-STAT3 branch in macrophage IFN-γ signaling.
Mees Botman, Josje M. A. Huisman, A. Drakaki, Sanne L. Maas +5 more
2026Cell Reports1 citations Open access
Semantic Scholar
A non-canonical EZH2/TRIM28 epigenetic axis drives heparan sulfate remodeling and melanoma metastasis
Neil G. Patel, A. Drakaki, Farhan Valummel, John Moore +11 more
2026bioRxiv1 citations
Semantic Scholar
Characterization of patients (pts) responding to enfortumab vedotin plus pembrolizumab (EV+P): Exploratory analysis from the phase 3 EV-302 trial of EV+P vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).
Shilpa Gupta, J. Bedke, M. S. van der Heijden, B. Valderrama +16 more
2026Journal of Clinical Oncology1 citations Open access
Semantic Scholar
FORAGER-2: A randomized phase 3 study evaluating the efficacy and safety of vepugratinib combined with enfortumab vedotin and pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma with an FGFR3 genetic alteration.
Melissa A. Reimers, G. Iyer, T. Powles, A. Drakaki +11 more
2026Journal of Clinical Oncology1 citations
Semantic Scholar
Sex Differences in Cancer and Cardiotoxicity: Mechanisms, Outcomes, and Clinical Implications Across Solid and Hematological Malignancies
K. Keramida, M. Aznar, J. Bergler-Klein, G. Boriani +10 more
2026Cancers1 citations Open access
Semantic Scholar
2Combination casdatifan plus cabozantinib in previously treated patients with clear cell renal cell carcinoma: results from an expansion cohort of ARC-20 (NCT05536141)
Toni Choueri, M. Ornstein, Pedro C. Barata, M. Matrana +15 more
2025The Oncologist1 citations Open access
Semantic Scholar
3070MO Phase I study of LY3866288, a potent, highly isoform-selective FGFR3 inhibitor in FGFR3-altered advanced solid tumors (FORAGER-1): Dose optimization
A. Drakaki, S. H. Park, D. C. Gauna, A. Siefker-Radtke +16 more
2025Annals of Oncology1 citations Open access
Semantic Scholar
Real world toxicity profile of enfortumab vedotin (EV) with or without pembrolizumab (P) in ultra elderly urothelial carcinoma (UC) patients (pts).
N. Mar, Jeanah Go, Marsenne Y. Cabral, D. Kaakour +3 more
2025Journal of Clinical Oncology1 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

T. Powles×17
Invite
T. Powles — researcher profile on SciRah
Y. Loriot×11
Invite
Y. Loriot — researcher profile on SciRah
M. Galsky×10
Invite
M. Galsky — researcher profile on SciRah
G. Iyer×8
Invite
G. Iyer — researcher profile on SciRah

×7

Invite

B. Valderrama — researcher profile on SciRah

Invite

J. Bedke — researcher profile on SciRah

J. Hoffman-Censits×6

Invite

J. Hoffman-Censits — researcher profile on SciRah

Invite

U. Swami — researcher profile on SciRah

Pedro C. Barata×6

Invite

Pedro C. Barata — researcher profile on SciRah

Invite

E. Kikuchi — researcher profile on SciRah

D. Castellano×5

Invite

D. Castellano — researcher profile on SciRah

Invite

N. Mar — researcher profile on SciRah